CMS 2005 Stakeholder Meeting To Discuss Future Of CLIA Quality Control
This article was originally published in The Gray Sheet
Executive Summary
CMS intends to address diagnostic quality control issues, such as whether FDA will enforce CLIA-related regulations on package inserts, during a March 18, 2005 stakeholder meeting
You may also be interested in...
CMS “Systems Approach” To Permit Equitable QC Testing Options Under CLIA
CLIA-regulated diagnostic manufacturers can change their package inserts and work with labs to take advantage of increased flexibility granted under CMS' new equitable quality control (EQC) testing options
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.